La Ciencia de la Medicina Regenerativa

Hassanshahi A, Hassanshahi M, Khabbazi S, et al.

62% of treated patients achieved full ulcer recovery vs. 28% control; weekly topical application over 4 weeks.

Kim DH, Lee S, Kim HJ, et al.

Positive clinical outcomes across androgenetic, areata, and chemotherapy-induced alopecia; MSC and platelet-rich sources demonstrated best-quality evidence.

Wang Y, Lu X, He J, et al.

Safety profile established across five preclinical species; three active Phase 1 trials (including NCT06431152); translational pathway from bench to clinical supply outlined.

Bhattacharya SD, Bhattacharya A, Bhattacharya S, et al.

Catalogued safety data across bone, cartilage, tendon, and ligament applications; engineered exosomes combined with bioactive molecules show enhanced chondrogenesis.

Smoot C, Brickner M, Wilson B, et al.

FDA-approved GHRH analogs (tesamorelin) show IGF-1-mediated satellite cell activation; unapproved peptides BPC-157 and TB-500 lack adequate human RCT evidence despite favorable preclinical profiles.

Dehghani M, Akhavan-Rahnama M, Nazari M, et al.

Significant pain reduction and functional improvement at 6 months; positive MRI cartilage signal changes following intra-articular 5 cc EV injection.

Zhang Y, Chopp M, Meng Y, et al.

MSC-EVs cross the blood-brain barrier, suppress neuroinflammation, and promote neuroregeneration; superior functional outcomes vs. direct cell transplant in multiple injury models.

Kaur IP, Bhattacharya S, Bhardwaj K, et al.

Statistically significant improvement in hair density, shaft diameter, and follicle count at 3- and 6-month follow-up assessments.

Mao G, Zhang Z, Hu S, et al.

Meta-analysis supports chondroprotective, anti-inflammatory, and pain-reducing effects; scalable production advantages over live cell therapy confirmed across 14 preclinical studies.

Pinto H, Navarro-Bielsa A, Puig L, et al.

Exosomes demonstrate comparable or superior efficacy to PRP with reduced procedural variability; growth factor cargo delivery to dermal papilla cells validated across sources.

Ali G, Badshah F, Liu X, et al.

Stem cell-derived exosomes decrease MMP expression, increase collagen I and elastin, and modulate intracellular signaling; support both anti-aging and hair cycling pathways.

Ren Z, Bhattacharya S, Bhatt D, et al.

EV cargo content mapped to axonal injury, neuroinflammation, BBB breakdown, and glial activation pathways; framework proposed for EV subtype-specific TBI therapy.

Wiklander OPB, Brennan MÁ, Lötvall J, et al.

Safety and tolerability confirmed; no serious adverse events at any dose level; supports allogeneic EV sourcing at clinical scale.

Guo SC, Tao SC, Yin WJ, et al.

Significantly higher GAIS scores on exosome-treated side vs. saline (p = 0.005); improved skin texture, elasticity, and wrinkle depth measurements.

Zhu G, Zhang X, Wang Z, et al.

MSC-EVs enhance tendon revascularization, reduce scar tissue formation, and improve intracellular signaling; accelerated healing in multiple in vivo tendinopathy models.

Warnke PH, Humpe A, Springer I, et al.

Demonstrated feasibility of GMP-scale EV production; EVs promote all wound healing stages — anti-inflammation, proliferation, angiogenesis, and ECM remodeling.

Liang Y, Zhang D, Li L, et al.

Exosomes suppress MMP expression, upregulate type I collagen and elastin synthesis, and reverse UV-induced senescence markers in dermal fibroblasts.

Bhaskaran M, Bhatt D, Bhatt R, et al.

Glial progenitor cell EVs normalized miRNA profiles in injured brain tissue; reduced lesion volume and improved neurobehavioral outcomes at 28 days post-injury.

Diwan H, Tung R, Rana D, et al.

Faster re-epithelialization and reduced erythema following fractional laser resurfacing; no adverse events; improved recovery time vs. standard post-procedure care.

Otero-Ortega L, Laso-García F, Gómez-de Frutos MD, et al.

MNC-derived small EVs outperformed MSC-EVs in reducing infarct volume; microglia reactivity significantly reduced at 7 days; superior neuroprotective profile identified.